SWEDISH ORPHAN BIOVIT.SK1/ SE0000872095 /
2024-10-15 7:30:05 PM | Chg. -0.040 | Volume | Bid7:30:11 PM | Ask7:30:11 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
25.820EUR | -0.15% | 0 Turnover: 0.000 |
-Bid Size: - | -Ask Size: - | 9.27 bill.EUR | - | - |
GlobeNewswire
05-24
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Act...
GlobeNewswire
2021-09-07
Nature Medicine publishes positive phase 3 anakinra study results in patients with COVID-19 pneumoni...
GlobeNewswire
2020-12-22
FDA Approves KINERET® (anakinra) for the Treatment of Deficiency of IL-1 Receptor Antagonist (DIRA)
GlobeNewswire
2016-05-04
Swedish Orphan Biovitrum AB (publ): Bo Jesper Hansen sells 8 million shares
GlobeNewswire
2016-04-11
COMP recommends that Alprolix® maintains orphan designation for treatment of haemophilia B
GlobeNewswire
2016-03-24
European Commission approves transfer of marketing authorisation for Elocta® to Sobi
GlobeNewswire
2016-02-26
Sobi and Biogen receive positive opinion from CHMP for Alprolix® (rFIXFc) for the treatment of haemo...
GlobeNewswire
2016-02-26
Bo Jesper Hansen to step down as Chairman of Sobi - Håkan Björklund to be nominated as new Chairman ...
GlobeNewswire
2016-02-23
Sobi to initiate clinical development programs in acute gout and Still's disease, and receives US pa...
GlobeNewswire
2016-02-17
Invitation - Presentation of Sobi's fourth quarter and full year results 2015
GlobeNewswire
2016-01-28
Sobi to present new interim ASPIRE data at EAHAD congress suggesting that patients can reduce bleedi...
GlobeNewswire
2016-01-11
Sobi(TM) announces commercial launch of Elocta® in first countries in Europe